# # # #
Alpha synuclein is one of the most common proteins in our brains and it has long been associated with Parkinson’s. The protein appears to clump together forming dense clusters ( or “aggregates“) in the Parkinsonian brain, and this may be related to the progressive neurodegeneration.
Researchers have been desperately seeking small molecules that will break up (or dissociate) these aggregates in the hope that it will slow down the progression of PD and allow neurons to return to health.
One example of such a molecule is UCB0599, which is being clinically developed by the pharmaceutical company UCB. This week, UCB presented the first clinical results for UCB0599 from their Phase I trial.
In today’s post, we will look at what alpha synuclein is, review what is known about UCB0599, discuss the results of the study, and consider what comes next.
# # # #
Last week at the 2021 American Academy of Neurology virtual meeting a poster was presented by the pharmaceutical company UCB.
Here at SoPD HQ, we have been eagerly awaiting these results.
They were the findings from the first Phase I clinical trial of a new molecule called UCB0599.
What is UCB0599?
UCB0599 is a brain-penetrant, oral small molecule alpha-synuclein misfolding inhibitor.
What does that mean?